{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T21:00:19Z","timestamp":1775682019076,"version":"3.50.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T00:00:00Z","timestamp":1523577600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4,23]]},"DOI":"10.1093\/ibd\/izx097","type":"journal-article","created":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T07:34:06Z","timestamp":1523604846000},"page":"953-959","source":"Crossref","is-referenced-by-count":26,"title":["What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn\u2019s Disease Treated With Vedolizumab?"],"prefix":"10.1093","volume":"24","author":[{"given":"Timothy","family":"Card","sequence":"first","affiliation":[{"name":"Nottingham City Hospital, Hucknall Road, Nottingham, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Company Ltd, Cambridge, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huifang","family":"Liang","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc., Deerfield, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"Bhayat","sequence":"additional","affiliation":[{"name":"Takeda Development Centre Europe Ltd, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,4,13]]},"reference":[{"key":"key\n\t\t\t\t20181009112332961_CIT0001","doi-asserted-by":"crossref","first-page":"pii","DOI":"10.12688\/f1000research.7071.1","article-title":"Progressive multifocal leukoencephalopathy","volume":"4","author":"Adang","year":"2015","journal-title":"F1000Res"},{"key":"key\n\t\t\t\t20181009112332961_CIT0002","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","article-title":"Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis","volume":"9","author":"Tan","year":"2010","journal-title":"Lancet Neurol"},{"key":"key\n\t\t\t\t20181009112332961_CIT0003","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/practneurol-2011-000092","article-title":"Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring","volume":"12","author":"Hunt","year":"2012","journal-title":"Pract Neurol"},{"key":"key\n\t\t\t\t20181009112332961_CIT0004","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev.med.080708.082655","article-title":"Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies","volume":"61","author":"Major","year":"2010","journal-title":"Annu Rev Med"},{"key":"key\n\t\t\t\t20181009112332961_CIT0005","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20181009112332961_CIT0006","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s13365-016-0427-6","article-title":"Reassessing the risk of natalizumab-associated PML","volume":"22","author":"Berger","year":"2016","journal-title":"J Neurovirol"},{"key":"key\n\t\t\t\t20181009112332961_CIT0007","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/13550289809113482","article-title":"Progressive multifocal leukoencephalopathy in patients with HIV infection","volume":"4","author":"Berger","year":"1998","journal-title":"J Neurovirol"},{"key":"key\n\t\t\t\t20181009112332961_CIT0008","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s13365-015-0316-4","article-title":"Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy","volume":"21","author":"Dong-Si","year":"2015","journal-title":"J Neurovirol"},{"key":"key\n\t\t\t\t20181009112332961_CIT0009","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/ana.22408","article-title":"Progressive multifocal leukoencephalopathy in transplant recipients","volume":"70","author":"Mateen","year":"2011","journal-title":"Ann Neurol"},{"key":"key\n\t\t\t\t20181009112332961_CIT0010","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1212\/WNL.0b013e31821a446b","article-title":"Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Vermersch","year":"2011","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20181009112332961_CIT0011","author":"Takeda Pharmaceuticals America Inc. ENTYVIO\u00ae (vedolizumab) Prescribing Information","year":"2014"},{"key":"key\n\t\t\t\t20181009112332961_CIT0012","author":"Biogen Idec Inc. Tysabri (Natalizumab) Summary of Product Characteristics","year":"2016"},{"key":"key\n\t\t\t\t20181009112332961_CIT0013","author":"Takeda Pharma A\/S. ENTYVIO\u00ae (vedolizumab) Summary of Product Characteristics","year":"2014"},{"key":"key\n\t\t\t\t20181009112332961_CIT0014","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2217\/imt.12.85","article-title":"Vedolizumab for the treatment of ulcerative colitis and Crohn\u2019s disease","volume":"4","author":"McLean","year":"2012","journal-title":"Immunotherapy"},{"key":"key\n\t\t\t\t20181009112332961_CIT0015","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1124\/jpet.109.153973","article-title":"The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases","volume":"330","author":"Soler","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"key\n\t\t\t\t20181009112332961_CIT0016","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1002\/ibd.22940","article-title":"Exclusive antagonism of the \u03b14 \u03b27 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates","volume":"18","author":"Fedyk","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20181009112332961_CIT0017","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jneuroim.2013.08.011","article-title":"Vedolizumab, a monoclonal antibody to the gut homing \u03b14\u03b27 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype","volume":"264","author":"Milch","year":"2013","journal-title":"J Neuroimmunol"},{"key":"key\n\t\t\t\t20181009112332961_CIT0018","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20181009112332961_CIT0019","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20181009112332961_CIT0020","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn\u2019s disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20181009112332961_CIT0021","author":"Biogen Idec Inc. Tysabri (Natalizumab) Prescribing information","year":"2015"},{"key":"key\n\t\t\t\t20181009112332961_CIT0022","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"key\n\t\t\t\t20181009112332961_CIT0023","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/ana.24371","article-title":"Persistence and pathogenesis of the neurotropic polyomavirus JC","volume":"77","author":"Wollebo","year":"2015","journal-title":"Ann Neurol"},{"key":"key\n\t\t\t\t20181009112332961_CIT0024","doi-asserted-by":"crossref","first-page":"S-768","DOI":"10.1016\/S0016-5085(11)63189-2","article-title":"Evaluation of the incidence of anti-JC virus antibodies in a cohort of natalizumab-treated patients","volume":"140","author":"Pepio","year":"2011","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20181009112332961_CIT0025","author":"Cytel Software Corporation"},{"key":"key\n\t\t\t\t20181009112332961_CIT0026","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1212\/WNL.0b013e3181f73600","article-title":"Incidence of progressive multifocal leukoencephalopathy in patients without HIV","volume":"75","author":"Amend","year":"2010","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20181009112332961_CIT0027","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1136\/annrheumdis-2012-201638","article-title":"Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study","volume":"71","author":"Arkema","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20181009112332961_CIT0028","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1086\/595299","article-title":"Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study","volume":"199","author":"Engsig","year":"2009","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20181009112332961_CIT0029","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1086\/598335","article-title":"Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study","volume":"48","author":"Khanna","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20181009112332961_CIT0030","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1634\/theoncologist.2010-0098","article-title":"Inclusion of rituximab in treatment protocols for non-Hodgkin\u2019s lymphomas and risk for progressive multifocal leukoencephalopathy","volume":"15","author":"Tuccori","year":"2010","journal-title":"Oncologist"},{"key":"key\n\t\t\t\t20181009112332961_CIT0031","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/00031305.1997.10473947","article-title":"A look at the rule of three","volume":"51","author":"Jovanovic","year":"1997","journal-title":"Am Stat"},{"key":"key\n\t\t\t\t20181009112332961_CIT0032","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1002\/art.24966","article-title":"Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases","volume":"60","author":"Molloy","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20181009112332961_CIT0033","doi-asserted-by":"crossref","DOI":"10.1111\/fcp.12247","article-title":"Drug-induced progressive multifocal leukoencephalopathy: a case\/noncase study in the French pharmacovigilance database","author":"Colin","year":"2017;31:237\u2013244","journal-title":"Fundam Clin Pharmacol"},{"key":"key\n\t\t\t\t20181009112332961_CIT0034","doi-asserted-by":"crossref","first-page":"e000823","DOI":"10.1136\/bmjopen-2012-000823","article-title":"Thirty-day mortality after elective and emergency total colectomy in danish patients with inflammatory bowel disease: a population-based nationwide cohort study","volume":"2","author":"T\u00f8ttrup","year":"2012","journal-title":"BMJ Open"},{"key":"key\n\t\t\t\t20181009112332961_CIT0035","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1136\/gutjnl-2013-306711","article-title":"Use of azathioprine in IBD: modern aspects of an old drug","volume":"63","author":"Louis","year":"2014","journal-title":"Gut"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/24\/5\/953\/25984120\/izx097.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T00:09:22Z","timestamp":1720224562000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/24\/5\/953\/4969878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,13]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,4,13]]},"published-print":{"date-parts":[[2018,4,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izx097","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,5]]},"published":{"date-parts":[[2018,4,13]]}}}